<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30666" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tuberous Sclerosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zamora</surname>
            <given-names>Edgar A.</given-names>
          </name>
          <aff>Montefiore Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aeddula</surname>
            <given-names>Narothama R.</given-names>
          </name>
          <aff>Deaconess HS, IN University School Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edgar Zamora declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Narothama Aeddula declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30666.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the formation of benign tumors in various organs of the body, including the brain, skin, kidneys, heart, lungs, and eyes. These tumors, known as hamartomas, can lead to a wide range of symptoms and complications, such as seizures, developmental delays, intellectual disabilities, skin abnormalities, and kidney problems. TSC affects individuals differently, with some experiencing mild symptoms while others face more severe manifestations. Its diagnosis often involves a multidisciplinary approach, combining clinical evaluation, imaging studies, and genetic testing. Although there is currently no cure for TSC, treatment focuses on managing symptoms and complications to improve the quality of life for affected individuals. This activity highlights the evaluation and management of TSC, shedding light on the critical role played by different members of the interprofessional team. By working collaboratively, healthcare professionals offer comprehensive and well-coordinated care to both patients and their families, aiming to optimize outcomes in managing this complex condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify clinical manifestations indicative of tuberous sclerosis complex across diverse age groups and developmental stages.</p></list-item><list-item><p>Determine appropriate imaging modalities for the screening and surveillance of tuberous sclerosis-related lesions in affected individuals.</p></list-item><list-item><p>Implement evidence-based management strategies for tuberous sclerosis-related neurological, dermatological, renal, pulmonary, and systemic manifestations.</p></list-item><list-item><p>Collaborate with interprofessional specialists from various disciplines to ensure comprehensive care and support for individuals with tuberous sclerosis complex.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30666&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30666">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30666.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tuberous sclerosis complex (TSC) is a genetic disorder inherited in an autosomal dominant fashion&#x000a0;and&#x000a0;is&#x000a0;characterized&#x000a0;by an increased predisposition to hamartoma formation.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref>&#x000a0;TSC results from mutations in the genes&#x000a0;<italic toggle="yes">TSC1&#x000a0;</italic>and&#x000a0;<italic toggle="yes">TSC2&#x000a0;</italic>and is known for causing neurological disorders, including epilepsy and intellectual disability.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;Other organ systems involved include pulmonary, renal, dermatologic, and cardiac. TSC&#x000a0;is usually diagnosed&#x000a0;in childhood or infancy, and the affected individuals may present with developmental delay, skin manifestations, or seizures. However, it may also&#x000a0;be diagnosed&#x000a0;earlier or later based on various clinical manifestations.<xref ref-type="bibr" rid="article-30666.r3">[3]</xref></p>
        <p>Some manifestations, such as cardiac rhabdomyomas or cortical tubers, may be present prenatally. Other signs, including renal and pulmonary lesions, are commonly diagnosed in adulthood.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref><xref ref-type="bibr" rid="article-30666.r3">[3]</xref>&#x000a0;The presentation of the disease will vary depending on the individual's developmental stage. While skin lesions&#x000a0;are detected&#x000a0;in 90% of patients of all ages, hypopigmented macules&#x000a0;are usually found&#x000a0;in early childhood. Ungual fibromas appear near puberty, and facial&#x000a0;angiofibromas&#x000a0;are more common in adolescence.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;This disease has a highly variable clinical course. The prognosis may be uncertain, and follow-up requires a comprehensive evaluation, often in specialized institutions. This disorder may be overwhelming for some patients and family members; thus, education and counseling play a vital role.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref><xref ref-type="bibr" rid="article-30666.r4">[4]</xref></p>
      </sec>
      <sec id="article-30666.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Tuberous sclerosis complex arises from mutations in the genes&#x000a0;<italic toggle="yes">TSC1&#x000a0;</italic>(9q34) or&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;(16p13.3), encoding hamartin and tuberin, respectively.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref><xref ref-type="bibr" rid="article-30666.r5">[5]</xref>&#x000a0;A broad spectrum of mutations has&#x000a0;been described&#x000a0;in both genes and while no particular regions seem more liable to mutations, the frequency is consistently higher for&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;than&#x000a0;<italic toggle="yes">TSC1</italic>.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;Among patients who meet the clinical criteria for tuberous sclerosis, approximately 15% have no identifiable genetic mutations.<xref ref-type="bibr" rid="article-30666.r6">[6]</xref></p>
        <p>
<bold><italic toggle="yes">TSC1</italic>&#x000a0;and<italic toggle="yes">&#x000a0;TSC2&#x000a0;</italic>Gene Mutations</bold>
</p>
        <p>There are 2 specific gene mutations:</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">TSC1&#x000a0;</italic>mutation occurs on chromosome 9 and is related to hamartin protein production.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">TSC2</italic>&#x000a0;is on chromosome 16 and affects tuberin protein production.</p>
          </list-item>
        </list>
        <p>These genes&#x000a0;are thought&#x000a0;to cause the characteristic tumors of the condition. The gene mutation may be inherited or may occur spontaneously. Most cases present sporadically, with no known family history, but approximately 1 in 3 patients inherit a defective&#x000a0;<italic toggle="yes">TSC1</italic>&#x000a0;or&#x000a0;<italic toggle="yes">TSC2&#x000a0;</italic>gene. If a parent has tuberous sclerosis, their children will carry a 50% risk of inheriting the disease. Because it follows an autosomal dominant inheritance pattern, and men and women are equally affected.</p>
        <p>
<bold>Hamartin and Tuberin Protein</bold>
</p>
        <p>Hamartin and tuberin play a role in a complex that controls cell growth and division in the body. These proteins modulate gene transcription and suppress tumor growth.<xref ref-type="bibr" rid="article-30666.r7">[7]</xref>&#x000a0;</p>
        <p>
<bold>Role in Central Nervous System Development</bold>
</p>
        <p><italic toggle="yes">TSC1/TSC2&#x000a0;</italic>mutations inactivate the inhibitory TSC protein complex, allowing aberrant activation of the mTOR pathways. The role of mTOR is to regulate cell growth and metabolism through the multimeric complexes mTORC1 and mTORC2. The complex mTORC1 integrates inputs from growth factors, amino acids, energy status, and hypoxia stressors to phosphorylate p70S6K and&#x000a0;4E-BP1 and promote cell proliferation. Without the TSC protein complex, the RAS homolog Rheb hyperactivates mTORC1. This reprogramming inhibits autophagy and favors anaerobic glycolysis. Therefore, mTORC1 aids solid tumor formation.<xref ref-type="bibr" rid="article-30666.r8">[8]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/167262#link_35246210">[14]</ext-link></p>
        <p>The mTOR pathway is especially significant in the central nervous and dermatologic systems. This pathway involves&#x000a0;neurocortical&#x000a0;lamination, neuronal migration, dendrite arborization, and neuronal polarity. Abnormalities in these processes contribute to the epilepsy and neurocognitive issues&#x000a0;found in TSC. The hyperactivity of mTOR also inhibits melanogenesis, leading to hypopigmented areas.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/167262#link_35246210">[12][14]</ext-link>&#x000a0; Tuberous sclerosis is also associated with vascular epithelial growth factor D, VEGF-D. Higher levels have&#x000a0;especially&#x000a0;been associated&#x000a0;with lymphangioleiomyomatosis and renal angiomyolipomas, and levels of VEGF-D have&#x000a0;been shown&#x000a0;to decrease with mTOR inhibition. However, this&#x000a0;is not commonly measured&#x000a0;outside of research settings.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/Keywords/UserViewPopup/167262#link_35246210">[14]</ext-link>&#x000a0;</p>
      </sec>
      <sec id="article-30666.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Tuberous sclerosis complex affects approximately 1 in 6000 to 1 in 10,000 live births, with an overall prevalence of 1 in 20,000. Clinical presentation is&#x000a0;extremely&#x000a0;variable, usually affecting multiple organs and involving all racial groups.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref>&#x000a0;In a longitudinal study involving 125 patients, the median age of presentation was&#x000a0;7&#x000a0;months.<xref ref-type="bibr" rid="article-30666.r9">[9]</xref>&#x000a0;Pulmonary lymphangioleiomyomatosis is usually diagnosed in women with TSC around age 35.<xref ref-type="bibr" rid="article-30666.r7">[7]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30666.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Tuberous sclerosis involves mutations in genes<italic toggle="yes">&#x000a0;TSC1&#x000a0;</italic>or&#x000a0;<italic toggle="yes">TSC2</italic>, which are<italic toggle="yes">&#x000a0;</italic>responsible for the production of proteins that regulate cell division and growth in the body. When gene mutations disrupt this balance, hamartomas may grow in the brain, skin, heart, kidney, liver, and lungs, affecting the function of these organs.<xref ref-type="bibr" rid="article-30666.r10">[10]</xref><xref ref-type="bibr" rid="article-30666.r11">[11]</xref><xref ref-type="bibr" rid="article-30666.r12">[12]</xref>&#x000a0;(See&#x000a0;<bold>Figure.</bold>&#x000a0;Tuberous Sclerosis Complex.)</p>
        <p>
<bold>Affected Areas and Organs</bold>
</p>
        <p>Tuberous sclerosis causes tumors to grow in multiple locations, resulting in a variation in the severity of the condition between individuals.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Dermatologic</bold>&#x000a0;manifestations include skin and nail lesions, which usually do not cause serious problems but can result in unwanted aesthetic effects.<xref ref-type="bibr" rid="article-30666.r13">[13]</xref>&#x000a0;&#x000a0;
<list list-type="bullet"><list-item><p>Skin lesions include facial&#x000a0;angiofibromas&#x000a0;(75%),&#x000a0;shagreen patches (&#x0003e;50%), ungual fibromas (20%&#x02013;80%), focal hypopigmentation (90%), and fibrous cephalic plaques (25%).<xref ref-type="bibr" rid="article-30666.r14">[14]</xref></p></list-item><list-item><p>In addition, retinal astrocytic hamartomas&#x000a0;were observed&#x000a0;in 40% to 50% of patients with TSC, especially those with gene mutations.<xref ref-type="bibr" rid="article-30666.r15">[15]</xref></p></list-item><list-item><p>Oral manifestations include gingival fibromas and dental enamel pits. The incidences are 20% to 50% and 90%, respectively.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Brain</bold>&#x000a0;tumors&#x000a0;often cause seizures or developmental delays. About 80% to 90% of TSC patients suffer from seizures.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Cortical, subcortical, and subependymal tubers are common; several studies have documented an association between the number of tubers with cognitive impairment and seizures.<xref ref-type="bibr" rid="article-30666.r16">[16]</xref><xref ref-type="bibr" rid="article-30666.r17">[17]</xref><xref ref-type="bibr" rid="article-30666.r18">[18]</xref>&#x000a0;</p></list-item><list-item><p>Subependymal nodules are seen in 80% to 90% of patients, while about 10% to 20% develop subependymal giant cell astrocytomas (SEGAs).<xref ref-type="bibr" rid="article-30666.r14">[14]</xref></p></list-item><list-item><p>Neurodevelopmental delays and behavioral issues are seen in up to 90% of patients with TSC and&#x000a0;are further discussed&#x000a0;in the history and physical section.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Renal</bold>&#x000a0;angiomyolipoma and cysts may affect renal function; complications include pain, bleeding, and possible renal failure.
<list list-type="bullet"><list-item><p>Angiomyolipomas are very common, affecting up to 75% of patients.&#x000a0;Please see StatPearls&#x02019; accompanying reference, &#x0201c;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17578">Renal Angiomyolipoma</ext-link>,&#x0201d; for further information.</p></list-item><list-item><p>More severe but less common renal manifestations include polycystic kidney disease (PKD) and renal cell carcinoma, with incidences of about 5% and 3%, respectively.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;The&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;and&#x000a0;<italic toggle="yes">PKD1</italic>&#x000a0;genes&#x000a0;are adjacently located; therefore, a&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;mutation can&#x000a0;be&#x000a0;partially or completely&#x000a0;accompanied&#x000a0;by&#x000a0;<italic toggle="yes">PKD1</italic>&#x000a0;mutation.&#x000a0;This&#x000a0;is called the contiguous gene syndrome. The renal phenotype in these patients is often&#x000a0;more severe, with early progression to renal failure. In addition, some TSC patients suffer from simple cystic disease without a&#x000a0;<italic toggle="yes">PKD1</italic>&#x000a0;mutation, and phenotypically, these patients are often indistinguishable.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref><xref ref-type="bibr" rid="article-30666.r33">[19]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Cardiac</bold>&#x000a0;rhabdomyomas are present in the majority of patients with TSC prenatally. Although they usually spontaneously regress by early childhood, cardiac&#x000a0;rhabdomyomas&#x000a0;can cause neonatal death. They can also re-present or occur de novo in adolescence, especially in girls.&#x000a0;About 20% of adults with TSC&#x000a0;are thought&#x000a0;to have cardiac&#x000a0;rhabdomyomas, but these are usually asymptomatic.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary</bold>&#x000a0;cysts and&#x000a0;lymphangioleiomyomatosis (LAM) can affect the lungs and are the most common cause of fatality for patients who exhibit evidence of this condition. The&#x000a0;incidence&#x000a0;of LAM in patients with tuberous sclerosis is about 30%, and the median age of diagnosis is about 35.<xref ref-type="bibr" rid="article-30666.r7">[7]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>This complication presents almost exclusively in women of childbearing age and worsens with high estrogen exposure, such as during pregnancy. Considered a low-grade neoplasm, it can also recur in transplanted lungs.<xref ref-type="bibr" rid="article-30666.r36">[20]</xref>&#x000a0;One study using screening by lung computed tomography (CT) scan of males with TSC found cystic lung changes in 10% to 38% of patients (men and women); however, only a&#x000a0;small&#x000a0;minority were symptomatic.<xref ref-type="bibr" rid="article-30666.r19">[21]</xref>&#x000a0;Please see StatPearls companion reference, &#x0201c;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/24552">Lymphangioleimyomatosis,</ext-link>&#x0201d; for further review.</p></list-item><list-item><p>Another possible pulmonary complication is&#x000a0;multifocal micronodular pneumocyte hyperplasia, which affects males and females equally and has an incidence of about 40% to 60%, although the vast majority are asymptomatic. This disease&#x000a0;is characterized&#x000a0;by small type II pneumocyte nodular lung deposits.<xref ref-type="bibr" rid="article-30666.r19">[21]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Hepatic</bold>&#x000a0;angiomyolipomas, cysts, and other benign lesions&#x000a0;are seen&#x000a0;in about 30% of patients with TSC, and some lesions grow significantly over time. However, these lesions are&#x000a0;largely&#x000a0;asymptomatic.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="22251200">[22]</ext-link></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30666.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Pulmonary pathology&#x000a0;</bold>
</p>
        <p>Lymphangioleiomyomatosis demonstrates diffuse, bilateral proliferation of smooth muscle-like cells in the lungs expressing melanocyte lineage markers, including gp100.&#x000a0;There are&#x000a0;2&#x000a0;types of LAM cells: small spindle-shaped cells&#x000a0;with eosinophilic cytoplasm&#x000a0;and epithelioid-like cells with abundant cytoplasm.<xref ref-type="bibr" rid="article-30666.r19">[19]</xref>&#x000a0;The gold standard for the pathologic diagnosis of LAM is immunoreactivity with the HMB-45 antibody, which recognizes gp100. These LAM cells exist within microscopic nodules containing other cell types, including lymphatic vessels and lymphocytes.<xref ref-type="bibr" rid="article-30666.r20">[20]</xref>&#x000a0;Both small spindle-shaped cells and epithelioid-like cells react with antibodies against smooth-muscle cell-specific antigens (eg,&#x000a0;&#x003b1;-actin, desmin, and vimentin). The cystic destruction of elastic fibers and collagen in the basal membrane of LAM cells&#x000a0;is mediated&#x000a0;by the secretion of matrix metalloproteinases.&#x000a0;Sex hormone receptors are always present in LAM cells. Interestingly, the muscle component of renal angiomyolipomas has an identical structure and immunohistochemical profile as LAM cells.<xref ref-type="bibr" rid="article-30666.r19">[19]</xref></p>
        <p>
<bold>Brain pathology</bold>
</p>
        <p>Cortical tubers include giant dysplastic neurons and astrocytes. Microtubers may also be present in normal-appearing white matter. Subependymal nodules are structures primarily arising along the lateral and third ventricle walls and are present in over 80% of patients with TSC. Approximately 5% to 15% of these tubers transform into subependymal giant cell astrocytomas (SEGAs). SEGAs&#x000a0;are comprised&#x000a0;of ganglion-like giant cells expressing neuronal and astrocytic markers.<xref ref-type="bibr" rid="article-30666.r21">[21]</xref></p>
        <p><bold>Skin lesions</bold>&#x000a0;</p>
        <p>Of the many skin manifestations seen in TSC, some common patterns emerge: concentric fibrosis/thickened collagen, vascular hyperplasia, fibroblast proliferation, and decreased elastic fibers. The most indicative of TSC is perifollicular fibrosis with atrophy and compression of the skin adnexa. Cascarino&#x000a0;et al&#x000a0;have methodically detailed the cutaneous findings as follows.<xref ref-type="bibr" rid="article-30666.r15">[15]</xref></p>
        <p><bold>Hypomelannotic&#x000a0;</bold>(ash-leaf) lesions demonstrate&#x000a0;a normal&#x000a0;density of active melanocytes but significantly decreased epidermal melanin pigment in the epidermis. Electron microscopy exhibits&#x000a0;a reduced number of&#x000a0;immature, smaller, and less melanized melanosomes in melanocytes and keratinocytes due to a lack&#x000a0;of mTOR pathway inhibition (which&#x000a0;normally&#x000a0;aids melanogenesis). Hypopigmented macules have&#x000a0;been microscopically studied&#x000a0;after topical rapamycin application. Topical rapamycin substantially improved hypopigmented macules and normalized some&#x000a0;of the&#x000a0;melanosome abnormalities in the treated skin.</p>
        <p><bold>Angiofibromas</bold>&#x000a0;present&#x000a0;as dome-shaped lesions with normal or sometimes hyperplastic epidermis. In the dermis, the collagen tissue and vascular structures expand hypertrophically. In older lesions, the collagen becomes more dense and sclerotic. Around the skin adnexa, a&#x000a0;perifollicular arrangement of collagen compresses these structures, sometimes replacing them with concentric collagen bundles. Other characteristics include dilated venules throughout, decreased or absent elastic tissue, and increased stellate cells clustering around the dilated blood vessels. Sometimes, multinucleated giant cells&#x000a0;are visualized. See <bold>Image.</bold>&#x000a0;Tuberous Sclerosis Angiofibroma.</p>
        <p><bold>Periungual Fibromas&#x000a0;</bold>have pathology similar to&#x000a0;angiofibromas but with increased vascularity and dense collagen that can extend to the hypodermis. Stellate cells are also present. See&#x000a0;<bold>Figure.</bold>&#x000a0;Periungual Fibroma of Tuberous Sclerosis.</p>
        <p><bold>Fibrous cephalic plaques&#x000a0;</bold>(forehead plaques) have&#x000a0;pathological features similar to angiofibromas.&#x000a0;Distinguishing features are more prominent vascular dilatation&#x000a0;and more&#x000a0;sclerosis and hyalinization of collagen with concentric perifollicular fibrosis causing atrophy and compression of the follicle.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Shagreen patches</bold>&#x000a0;are similar to collagenomas (or collagenic hamartomas).&#x000a0;The dermis&#x000a0;is replaced&#x000a0;by hyaline collagen, which&#x000a0;is dense and mostly acellular&#x000a0;extending&#x000a0;down to the subcutaneous fat.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>As with fibromas and forehead plaques, follicles show concentric perifollicular collagen with follicular atrophy and compression.&#x000a0;Elastic fibers are thin or absent.<xref ref-type="bibr" rid="article-30666.r15">[15]</xref>&#x000a0;See&#x000a0;<bold>Figure.</bold>&#x000a0;Shagreen Patch of Tuberous Sclerosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30666.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of TSC is highly variable, and manifestations will continue developing over a patient&#x02019;s lifetime.<xref ref-type="bibr" rid="article-30666.r5">[5]</xref>&#x000a0;Central nervous system manifestations are common. As noted above, seizures are present in up to 90% of patients with TSC, usually presenting before age 3.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;Subependymal giant cell astrocytomas are present in up to 20% of patients with TSC, usually presenting in the first&#x000a0;2&#x000a0;decades of life; they can cause mass effect, hydrocephalus, and even death.<xref ref-type="bibr" rid="article-30666.r16">[16]</xref><xref ref-type="bibr" rid="article-30666.r22">[22]</xref>&#x000a0;Neuropsychiatric manifestations are present in up to 90% of patients with TSC, including intellectual disability, behavioral difficulties, attention deficit hyperactivity disorder, obsessive-compulsive disorder, and autism spectrum disorders.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref><xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;About 50% of patients with TSC show signs of having autism spectrum disorder.&#x000a0;Some evidence shows improvement of all these entities with the use of mTOR inhibitors.<xref ref-type="bibr" rid="article-30666.r22">[22]</xref></p>
        <p>Skin manifestations are&#x000a0;very common, and various skin manifestations&#x000a0;are included&#x000a0;in the&#x000a0;major&#x000a0;criteria for diagnosing tuberous sclerosis. Facial&#x000a0;angiofibromas&#x000a0;present in 75% of patients.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref><xref ref-type="bibr" rid="article-30666.r3">[3]</xref>&#x000a0;Hypomelanotic macules are the most common dermatological manifestation, present in approximately 90% of patients as lighter patches of skin (ie, ash leaf or confetti lesions). Fibrous cephalic plaques present most commonly on the forehead, but they can be anywhere on the face or scalp. These plaques appear as&#x000a0;smooth or bumpy lesions, skin-colored, pink, red, or brown.<xref ref-type="bibr" rid="article-30666.r23">[23]</xref>&#x000a0;Facial&#x000a0;angiofibromas&#x000a0;commonly follow a butterfly or malar distribution&#x000a0;<xref ref-type="bibr" rid="article-30666.r24">[24]</xref>, while Shagreen patches are present in areas of thicker skin as a leathery lesion with a pebbly texture.<xref ref-type="bibr" rid="article-30666.r3">[3]</xref>&#x000a0;Periungual fibromas are also common and can appear after trauma; about 90% are on the toes. Please see StatPearls&#x02019; companion reference, &#x0201c;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17566">Cutaneous Angiofibromas,</ext-link>&#x0201d; for further information. See <bold>Image.</bold>&#x000a0;Tuberous Sclerosis Ash Leaf.</p>
        <p>Lymphangioleiomyomatosis (LAM) occurs primarily in women of childbearing age; studies have shown a wide range of patients with TSC who have radiographic imaging evidence of LAM, ranging from 30% to 80%, with rates increasing with age.&#x000a0;Fortunately, the vast of patients with LAM are asymptomatic and have only radiographic evidence of LAM.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="33304400">[28]</ext-link>&#x000a0;Presenting symptoms may be chest pain or dyspnea, which, when sudden, could represent a spontaneous pneumothorax.<xref ref-type="bibr" rid="article-30666.r36">[20]</xref>&#x000a0;Chylothorax is also a possible presentation and can present with progressive dyspnea or&#x000a0;chyloptysis.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23952870">[29]</ext-link></p>
        <p>Cardiac lesions may be present in 50% to 70% of patients at some time. As noted above&#x000a0;the&#x000a0;lesions can cause neonatal death, but they often regress by early childhood.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;A case series involving 125 patients reported that cardiac&#x000a0;rhabdomyomas&#x000a0;were the second most common presentation of TSC in early childhood or infancy (second to seizures).<xref ref-type="bibr" rid="article-30666.r9">[9]</xref>&#x000a0;Renal angiomyolipomas may manifest in 55% to 75% of patients.<xref ref-type="bibr" rid="article-30666.r6">[6]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="9628635">[30]</ext-link>&#x000a0;Incidence&#x000a0;increases with age, and a longitudinal study showed a 75% prevalence of renal angiomyolipomas by the age of 10.5 years.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="9628635">[30]</ext-link>&#x000a0;These angiomyolipomas are often asymptomatic, but symptoms can include flank pain, hemorrhage, hematuria, and a tender abdominal mass.<xref ref-type="bibr" rid="article-30666.r36">[20]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="12354988">[31]</ext-link>&#x000a0;The diagnosis of tuberous sclerosis, discussed below, consists of major and minor clinical criteria.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;The diagnosis is often first made during childhood, when several dermatological features may become apparent.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="21173003">[32]</ext-link></p>
      </sec>
      <sec id="article-30666.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Tuberous sclerosis is mainly diagnosed based on clinical criteria, but it can also be diagnosed with genetic testing. Genetic testing is not required if a patient fulfills the clinical criteria,&#x000a0;although&#x000a0;it may provide useful information for other family members.<xref ref-type="bibr" rid="article-30666.r5">[5]</xref>&#x000a0;Genetic testing of&#x000a0;<italic toggle="yes">TSC1&#x000a0;</italic>and&#x000a0;<italic toggle="yes">TSC2&#x000a0;</italic>is positive for mutations in 75% to 95% of individuals affected with TSC. Currently, reliable screening tests for&#x000a0;<italic toggle="yes">TSC1&#x000a0;</italic>and&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;detect pathogenic mutations causing inactivation of the&#x000a0;<italic toggle="yes">TSC1&#x000a0;</italic>or&#x000a0;<italic toggle="yes">TSC2</italic>&#x000a0;proteins, leading to the loss of inhibition of mTOR.<xref ref-type="bibr" rid="article-30666.r25">[25]</xref><xref ref-type="bibr" rid="article-30666.r26">[26]</xref></p>
        <p>As per the recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference, the diagnostic criteria for tuberous sclerosis include the following&#x000a0;major&#x000a0;and minor features:</p>
        <p>
<bold>Major Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypomelanotic macules (&#x0003e;2&#x000a0;at least 5 mm in diameter)</p>
          </list-item>
          <list-item>
            <p>Angiofibromas (&#x0003e;2) or a fibrous cephalic plaque</p>
          </list-item>
          <list-item>
            <p>Ungual fibromas (&#x0003e;1)</p>
          </list-item>
          <list-item>
            <p>Shagreen patch</p>
          </list-item>
          <list-item>
            <p>Multiple retinal hamartomas</p>
          </list-item>
          <list-item>
            <p>Cortical dysplasias</p>
          </list-item>
          <list-item>
            <p>Subependymal nodules</p>
          </list-item>
          <list-item>
            <p>Subependymal giant cell astrocytoma</p>
          </list-item>
          <list-item>
            <p>Cardiac rhabdomyoma</p>
          </list-item>
          <list-item>
            <p>Lymphangioleiomyomatosis</p>
          </list-item>
          <list-item>
            <p>Angiomyolipomas (&#x0003e;1)</p>
          </list-item>
        </list>
        <p>
<bold>Minor Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Confetti skin lesions</p>
          </list-item>
          <list-item>
            <p>Dental enamel pits (&#x0003e;3)</p>
          </list-item>
          <list-item>
            <p>Intraoral fibromas (&#x0003e;1)</p>
          </list-item>
          <list-item>
            <p>Retinal achromic patch</p>
          </list-item>
          <list-item>
            <p>Multiple renal cysts</p>
          </list-item>
          <list-item>
            <p>Nonrenal hamartomas&#x000a0;<xref ref-type="bibr" rid="article-30666.r5">[5]</xref><xref ref-type="bibr" rid="article-30666.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>Definitive diagnosis is established in patients with&#x000a0;2&#x000a0;major features or&#x000a0;1&#x000a0;major&#x000a0;feature with at least&#x000a0;2&#x000a0;minor features, while &#x0201c;possible diagnosis&#x0201d; is recognized in patients with&#x000a0;1&#x000a0;major&#x000a0;feature or at least&#x000a0;2&#x000a0;minor features.<xref ref-type="bibr" rid="article-30666.r5">[5]</xref><xref ref-type="bibr" rid="article-30666.r27">[27]</xref>&#x000a0;The appropriate diagnosis should&#x000a0;be made&#x000a0;using&#x000a0;either&#x000a0;clinical&#x000a0;criteria or genetic testing.&#x000a0;As most patients present with dermatological features, the physical examination should include a careful skin examination&#x000a0;using&#x000a0;a Wood&#x02019;s lamp to&#x000a0;locate hypomelanotic lesions.<xref ref-type="bibr" rid="article-30666.r13">[13]</xref>&#x000a0;In addition,&#x000a0;a thorough funduscopic examination is warranted to evaluate for retinal hamartomas.&#x000a0;Imaging tests&#x000a0;prove useful&#x000a0;in identifying lesions such as cardiac&#x000a0;rhabdomyomas&#x000a0;through echocardiography. Intracranial tubers and subependymal tumors can&#x000a0;be visualized&#x000a0;through magnetic resonance imaging (MRI) or CT. Renal angiomyolipomas can&#x000a0;be identified&#x000a0;by either ultrasonography, CT, or MRI, but they generally require CT or MRI to rule out malignancy and fully characterize the lesion.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref></p>
      </sec>
      <sec id="article-30666.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The 2012 TSC consensus recommended that patients undergo lifetime surveillance to monitor for common manifestations.<xref ref-type="bibr" rid="article-30666.r5">[5]</xref> For children with tuberous sclerosis, an every 1- or 3-year lifetime surveillance, including imaging studies, has been suggested.<xref ref-type="bibr" rid="article-30666.r4">[4]</xref><xref ref-type="bibr" rid="article-30666.r27">[27]</xref>&#x000a0;As discussed, the follow-up for TSC should be comprehensive, and it commonly presents a wide variety of multi-systemic complications. A comprehensive dermatologic evaluation may aid in the early recognition of angiofibromas that may eventually cause cosmetic disfigurations&#x000a0;requiring laser therapy or surgical removal.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;Skin and dermatologic manifestations are also often responsive to mTOR inhibitors. Topical rapamycin has also been used with good effect for neural angiofibromas and seems to be more efficacious in children than adults with fewer adverse effects than systemic mTOR administration.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref><xref ref-type="bibr" rid="article-30666.r15">[15]</xref></p>
        <p>Anticonvulsants are often required for TSC-associated epilepsy, especially vigabatrin for infantile spasms. However, about one-third of patients have treatment-refractory seizures, and surgery may be needed. Emergent neurosurgery may also be required for complications like hydrocephalus.<xref ref-type="bibr" rid="article-30666.r22">[22]</xref>&#x000a0;As recommended by the 2012 consensus for tuberous sclerosis, treatment of acutely symptomatic subependymal giant cell astrocytomas (SEGA) (primarily complications of obstructive hydrocephalus) is surgical resection.<xref ref-type="bibr" rid="article-30666.r27">[27]</xref> Surgical resection for symptomatic SEGA, however, is associated with a substantial increase in mortality and comorbidities, including hemiparesis, bleeding, infection, and cognitive decline. Asymptomatic SEGA is usually treated with mTOR inhibitors, including sirolimus, everolimus, and rapamycin.<xref ref-type="bibr" rid="article-30666.r28">[28]</xref><xref ref-type="bibr" rid="article-30666.r29">[29]</xref></p>
        <p>For renal angiomyolipomas larger than 3.5 cm, arterial embolization is recommended to avoid total nephrectomy and decrease the incidence of renal complications. Despite this effort, however, the incidence of complications, including chronic kidney disease, is similar in TSC patients who undergo partial versus complete nephrectomy.<xref ref-type="bibr" rid="article-30666.r30">[30]</xref><xref ref-type="bibr" rid="article-30666.r31">[31]</xref>&#x000a0;For lesions measuring larger than 3 cm, treatment with mTOR inhibitors is considered first-line therapy. Bleeding from renal angiomyolipomas is a cause of mortality in TSC patients, and for those presenting with acutely bleeding renal angiomyolipoma, arterial embolization followed by corticosteroids is considered the treatment of choice.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref>&#x000a0;Post-embolization recurrence is common, and both arterial embolization and surgical removal (including nephron-sparing surgery) are second-line options if mTOR inhibition is not sufficient.</p>
        <p>Renal angiomyolipomas are present in 50% to 75% of patients with TSC. Indications for treatment are a size larger than 6 cm diameter, associated clinical symptoms, women desiring pregnancy, and other high-risk situations. Please see StatPearls accompanying reference, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/17578">Renal Angiomyolipoma</ext-link>," for further information. Both sirolimus and everolimus are used for renal angiomyolipoma treatment and and considered first-line treatments, preferable to surgical removal; these mTOR inhibitors are also used intermittently for maintenance therapy to prevent regrowth of the angiomyolipoma.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref><xref ref-type="bibr" rid="article-30666.r32">[32]</xref>&#x000a0;The use of mTOR inhibition has also been studied for associated polycystic kidney disease and renal cystic disease, and it is thought that mTOR inhibitors are effective in reducing cyst size and number.<xref ref-type="bibr" rid="article-30666.r33">[33]</xref></p>
        <p>Lymphangiomyomatosis (LAM) can also be treated with mTOR inhibitors.<xref ref-type="bibr" rid="article-30666.r34">[34]</xref>&#x000a0;European Respiratory System guidelines recommend screening all females for LAM starting at age 18 and then every 5 to 7 years until menopause thereafter, or if they develop respiratory symptoms, or in males with respiratory symptoms.<xref ref-type="bibr" rid="article-30666.r13">[13]</xref><xref ref-type="bibr" rid="article-30666.r35">[35]</xref> For patients with LAM, some sources recommend follow-up with an annual pulmonary function test to monitor for lung function deterioration.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;Chylothorax occurs in about 7% to 10% of patients with LAM and has traditionally been treated with a fat-free or low-fat diet, which can be restrictive and place patients at risk for malnutrition. Thoracentesis, pleurodesis, and thoracic duct ligation are surgical techniques that have also been used. However, multiple recent studies have shown sirolimus effective in controlling this rare complication.<xref ref-type="bibr" rid="article-30666.r36">[36]</xref></p>
      </sec>
      <sec id="article-30666.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis will vary and depend on each case's clinical manifestations. Some possible conditions in the differential diagnosis include the following:&#x000a0;TSC and neurofibromatosis type 1 (NF1) are&#x000a0;both&#x000a0;neurocutaneous disorders with autosomal dominant inheritance. NF1 is not usually associated with neurocognitive problems and seizures, both of which are extremely common with TSC. The morbidity of NF1 is primarily related to central nervous system and nerve sheath tumors. NF1 is diagnosed with multiple cafe-au-lait spots and may be associated with bone deformities. Other neurocutaneous syndromes with similar symptoms include&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/25787">neurofibromatosis type 2</ext-link>, ataxia telangiectasia,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/31268">von Hippel Lindau syndrome</ext-link>, and Sturge-Weber syndrome. Please see the associated references for further review.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="27884168">[43]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="28126187">[44]</ext-link>&#x000a0;Birt-Hogg-Dub&#x000e9;&#x000a0;syndrome&#x000a0;and multiple endocrine neoplasia type 1 (MEN1) can present with facial&#x000a0;angiofibromas, but these usually develop at a later age than in TSC.<xref ref-type="bibr" rid="article-30666.r5">[5]</xref></p>
      </sec>
      <sec id="article-30666.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for TSC includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Each patient will present different manifestations of the disease and will, therefore, follow different clinical courses.<xref ref-type="bibr" rid="article-30666.r4">[4]</xref>&#x000a0;The morbidity of TSC is quite significant for patients and caregivers. In addition, mortality is significantly higher than in patients without TSC, and various long-term studies report mortality at 4.8% to 8.3% at a follow-up range of 8 to 17.4 years.<xref ref-type="bibr" rid="article-30666.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Mortality is most often caused by complications of seizures or renal angiomyolipomas.<xref ref-type="bibr" rid="article-30666.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Other causes of mortality include bronchopneumonia, complications of LAM, and neonatal heart failure related to rhabdomyomas.<xref ref-type="bibr" rid="article-30666.r14">[14]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The 5-year survival rate of patients receiving lung transplants due to LAM is about 65%.<xref ref-type="bibr" rid="article-30666.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30666.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Tuberous sclerosis affects multiple systems and may manifest in various tissues within a lifetime. As detailed above, renal manifestations are common in patients with tuberous sclerosis complex, especially renal angiomyolipomas. Other common renal lesions include polycystic kidney disease, renal cysts, and renal cell carcinomas (RCC). The latter has a similar lifetime risk to the general population; however, they usually&#x000a0;present at a younger age.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;</p>
        <p>Up to 56% of patients with lymphangioleiomyomatosis (LAM) may develop pneumothorax, and of those who do, recurrence is likely, with an average recurrence of 4.4 times. For this reason, pleurodesis is recommended in patients who develop pneumothorax, although even with this procedure, the recurrence rate is between 18% and 32%.<xref ref-type="bibr" rid="article-30666.r36">[36]</xref>&#x000a0;A newer surgical technique called total pleural covering uses&#x000a0;oxidized regenerated cellulose mesh to wrap the visceral pleura and has shown promising outcomes.<xref ref-type="bibr" rid="article-30666.r36">[36]</xref><xref ref-type="bibr" rid="article-30666.r38">[38]</xref></p>
        <p>In addition, patients with LAM are more likely to develop pneumothorax with air travel (which involves changes in barometric pressure). One study found the rate at 1.1% per flight in LAM patients.<xref ref-type="bibr" rid="article-30666.r36">[36]</xref><xref ref-type="bibr" rid="article-30666.r20">[20]</xref>&#x000a0;Subependymal giant cell astrocytomas may cause obstructive hydrocephalus due to their location near Monro's foramen and size. As previously discussed, surgery for these lesions also carries a substantial risk of mortality and other complications.<xref ref-type="bibr" rid="article-30666.r39">[39]</xref><xref ref-type="bibr" rid="article-30666.r40">[40]</xref>&#x000a0;Seizures are common in tuberous sclerosis and often refractory to medical treatment;&#x000a0;for this reason, they may need to be treated surgically.<xref ref-type="bibr" rid="article-30666.r3">[3]</xref></p>
        <p>Although mTOR inhibitors have greatly improved the prognosis and decreased morbidity and mortality of TSC, they still have associated adverse effects, including stomatitis, increased infections, and menstrual irregularities. The most serious adverse event associated with everolimus in one long-term study was pneumonia; results also found adverse effects were more severe in children than adults.<xref ref-type="bibr" rid="article-30666.r41">[41]</xref>&#x000a0;Less common adverse effects include skin rash, hyperlipidemia, hyperglycemia, myelosuppression, and proteinuria. Less severe adverse effects can usually be treated with temporary cessation or dose reduction.<xref ref-type="bibr" rid="article-30666.r38">[38]</xref></p>
      </sec>
      <sec id="article-30666.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>The following healthcare professions can provide consults for this condition:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatrics</p>
          </list-item>
          <list-item>
            <p>Nephrology</p>
          </list-item>
          <list-item>
            <p>Neurology</p>
          </list-item>
          <list-item>
            <p>Neurosurgery</p>
          </list-item>
          <list-item>
            <p>Cardiology</p>
          </list-item>
          <list-item>
            <p>Ophthalmology</p>
          </list-item>
          <list-item>
            <p>Dermatology</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30666.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Tuberous sclerosis is a disease with a highly variable clinical course and has a wide range of possible manifestations. As such, the uncertainty and complexity of this disease may be daunting, particularly for family members.<xref ref-type="bibr" rid="article-30666.r1">[1]</xref><xref ref-type="bibr" rid="article-30666.r4">[4]</xref>&#x000a0;Genetic counseling is useful for patients and parents of children with&#x000a0;tuberous sclerosis complex. Those parents affected should be advised that the risk of having an affected child is approximately 50%.<xref ref-type="bibr" rid="article-30666.r2">[2]</xref>&#x000a0;For parents who are not affected by the disease, the risk of having another child with TSC is around 1% to 2%. Parents may also be tested as they present the disease after their children (parents may present mosaicism).<xref ref-type="bibr" rid="article-30666.r42">[42]</xref>&#x000a0;</p>
        <p>As noted above, estrogen exposure (through birth control pills or pregnancy) can worsen LAM symptoms, and women should be counseled in advance of pregnancy regarding the use of birth control pills with estrogen. &#x000a0;Patients with LAM are also at risk of spontaneous pneumothorax, especially with a history of pneumothorax or with air travel, and should be educated about these risks. They should also receive appropriate pneumovax and other vaccines for upper respiratory infections.<xref ref-type="bibr" rid="article-30666.r20">[20]</xref>&#x000a0;Patients should be counseled on using sunscreen, especially on hypomelanotic lesions.<xref ref-type="bibr" rid="article-30666.r13">[13]</xref><xref ref-type="bibr" rid="article-30666.r35">[35]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30666.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>About 75% to 90% of patients with SC carry a mutation in <italic toggle="yes">TSC1</italic> or <italic toggle="yes">TSC2</italic>, which encodes the proteins hamartin and tuberin, which are inhibitor complexes considered to be tumor suppressor genes. Mutations in these proteins cause benign brain, skin, lung, heart, liver, and kidney hamartomas. Neurologic and dermatologic involvement are the most prominent early symptoms. About 90% of patients will have neurologic symptoms, including epilepsy and neurocognitive issues; infantile spasms requiring treatment with vigabatrin are especially common. About 90% will have dermatologic manifestations, with focal hypomelanotic areas (ash leaf lesions) being the most common. Other common dermatologic manifestations are facial angiofibromas, shagreen patches, ungual fibromas, and fibrous cephalic plaques. In addition, retinal astrocytic hamartomas are seen in 40% to 50% of patients with TSC, especially those with gene mutations.</p>
        <p>Renal angiomyolipomas are present in about 75% of patients by age 10. The likelihood of bleeding or other complications is related to size, vascularity, and other factors. Mortality is highly linked to complications of seizures and renal angiomyolipomas. Lymphangioleiomyomatosis is the presence of smooth muscle tissue in the lungs associated with cystic loss of lung parenchyma. It is most common in women of childbearing age, and while many TSC patients have radiographic evidence of LAM, symptomatic LAM is much less common. Many experts recommend against estrogen-containing birth control pills as this could exacerbate LAM progression in women. Progesterone-only pills do not seem to have the same exacerbating effect. Pregnancy must be undertaken cautiously for the same reason, and pregnant women require frequent monitoring. The recognition that mTOR inhibitors (rapamycin, sirolimus, everolimus) greatly slow the progression of hamartomas in many tissues, including the brain, kidney, lung, and skin, has greatly changed the management of TSC. Surgical management is still warranted in some cases, and genetic counseling is advised, given the autosomal dominant nature of the disease.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-30666.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with tuberous sclerosis are best managed&#x000a0;with an interprofessional team approach.&#x000a0;Specialties&#x000a0;include primary care providers, pediatrics, dermatology, nephrology, neurology, neurosurgery, cardiology, ophthalmology, radiology, surgery, and interventional radiology. Primary care providers and pediatricians should provide annual examinations for patients with tuberous sclerosis, focusing on the common manifestations and complications of tuberous sclerosis, and conduct a thorough multisystemic history and physical.&#x000a0;Several clinics in the United States specialize in the follow-up and care of patients with tuberous sclerosis. Referral of patients to these centers should ensure that they will receive a comprehensive follow-up. When this is impossible, individual specialty referral should&#x000a0;be conducted&#x000a0;for the different manifestations, such as epilepsy,&#x000a0;lymphangioleiomyomatosis, and renal angiomyolipomas.</p>
        <p>A strategic approach is equally crucial, involving evidence-based strategies to optimize treatment plans and minimize&#x000a0;adverse effects. Ethical considerations must guide decision-making, ensuring informed consent and respecting patient autonomy in treatment choices. Each healthcare professional must&#x000a0;know&#x000a0;their responsibilities and contribute their unique expertise to the patient&#x02019;s care plan, fostering a multidisciplinary approach. Effective interprofessional communication is paramount, allowing seamless information exchange and collaborative decision-making among the team members. Care coordination plays a pivotal role in ensuring that the patient&#x02019;s journey from diagnosis to treatment and follow-up is well-managed, minimizing errors and enhancing patient safety. By embracing these principles of skill, strategy, ethics, responsibilities, interprofessional communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the management of tuberous sclerosis.</p>
      </sec>
      <sec id="article-30666.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30666&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30666">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/tuberous-sclerosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30666">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30666/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30666">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30666.s18">
        <fig id="article-30666.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Facial Angiofibromas Observed in Tuberous Sclerosis. Facial angiofibromas are considered one of the most apparent clinical presentations of tuberous sclerosis, an autosomal dominant hamartomatous disorder that affects the skin, kidneys, heart, brain, and lungs. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tuberous__sclerosis__angiofibromas" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30666.s19">
        <fig id="article-30666.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Tuberous Sclerosis Ash Leaf. The ash-leaf spot is the earliest skin lesion in patients with tuberous sclerosis. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tuberous__sclerosis__ash__leaf" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30666.s20">
        <fig id="article-30666.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Shagreen Patch of Tuberous Sclerosis. These patches are specific for tuberous sclerosis and present as large plaques on the lower back, with a bumpy or orange-peel surface. They appear commonly in children younger than 10. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/image-library">Dermnet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tuberous-sclerosis-ShagreenPatch" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30666.s21">
        <fig id="article-30666.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Periungual Fibroma of Tuberous Sclerosis. The pathology of this fibroma is similar to angiofibromas, but with increased vascularity and dense collagen that can extend to the hypodermis. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/image-library">DermNet New Zealand&#x000a0;</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="periungual-fibroma4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30666.s22">
        <title>References</title>
        <ref id="article-30666.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Waele</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lagae</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mekahli</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis complex: the past and the future.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>1771</fpage>
            <page-range>1771-80</page-range>
            <pub-id pub-id-type="pmid">25533384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crino</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Nathanson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>The tuberous sclerosis complex.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Sep</month>
            <day>28</day>
            <volume>355</volume>
            <issue>13</issue>
            <fpage>1345</fpage>
            <page-range>1345-56</page-range>
            <pub-id pub-id-type="pmid">17005952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manoukian</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kowal</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive imaging manifestations of tuberous sclerosis.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2015</year>
            <month>May</month>
            <volume>204</volume>
            <issue>5</issue>
            <fpage>933</fpage>
            <page-range>933-43</page-range>
            <pub-id pub-id-type="pmid">25905927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Annual review of children with tuberous sclerosis.</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>100</volume>
            <issue>3</issue>
            <fpage>114</fpage>
            <page-range>114-21</page-range>
            <pub-id pub-id-type="pmid">25112285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Northrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
              <collab>International Tuberous Sclerosis Complex Consensus Group</collab>
            </person-group>
            <article-title>Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference.</article-title>
            <source>Pediatr Neurol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>243</fpage>
            <page-range>243-54</page-range>
            <pub-id pub-id-type="pmid">24053982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dabora</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Nieto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Reeve</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Egelhoff</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kasprzyk-Obara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Domanska-Pakiela</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.</article-title>
            <source>Am J Hum Genet</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-80</page-range>
            <pub-id pub-id-type="pmid">11112665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis - a wolf in sheep's clothing.</article-title>
            <source>J Clin Invest</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>122</volume>
            <issue>11</issue>
            <fpage>3807</fpage>
            <page-range>3807-16</page-range>
            <pub-id pub-id-type="pmid">23114603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saxton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sabatini</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>mTOR Signaling in Growth, Metabolism, and Disease.</article-title>
            <source>Cell</source>
            <year>2017</year>
            <month>Mar</month>
            <day>09</day>
            <volume>168</volume>
            <issue>6</issue>
            <fpage>960</fpage>
            <page-range>960-976</page-range>
            <pub-id pub-id-type="pmid">28283069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yates</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Maclean</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>le Mar&#x000e9;chal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carcani-Rathwell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>PF</given-names>
              </name>
              <collab>Tuberous Sclerosis 2000 Study Group</collab>
            </person-group>
            <article-title>The Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for diagnosis and management.</article-title>
            <source>Arch Dis Child</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>96</volume>
            <issue>11</issue>
            <fpage>1020</fpage>
            <page-range>1020-5</page-range>
            <pub-id pub-id-type="pmid">21813552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doubkov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x00160;tef&#x000e1;nikov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x0010c;an</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Merta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Svoboda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lymphangioleiomyomatosis.</article-title>
            <source>Klin Onkol</source>
            <year>2019</year>
            <season>Fall</season>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>367</fpage>
            <page-range>367-374</page-range>
            <pub-id pub-id-type="pmid">31610670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>GX</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Tuberous Sclerosis Complex in Chinese patients: Phenotypic analysis and mutational screening of TSC1/TSC2 genes.</article-title>
            <source>Seizure</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>71</volume>
            <fpage>322</fpage>
            <page-range>322-327</page-range>
            <pub-id pub-id-type="pmid">31525612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gruber</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Scholl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Samueli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gr&#x000f6;ppel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>M&#x000fc;hlebner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hainfellner</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of neurodevelopmental mTOR pathway-associated epileptic conditions: Current status of biomedical research.</article-title>
            <source>Clin Neuropathol</source>
            <year>2019</year>
            <season>Sep/Oct</season>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>210</fpage>
            <page-range>210-224</page-range>
            <pub-id pub-id-type="pmid">31347492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Northrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bebin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Bissler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Darling</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Gosnell</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Knilans</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>FX</given-names>
              </name>
              <name>
                <surname>Pounders</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roberds</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rodriguez-Buritica</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sparagana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Wheless</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
              <collab>International Tuberous Sclerosis Complex Consensus Group</collab>
            </person-group>
            <article-title>Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.</article-title>
            <source>Pediatr Neurol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>123</volume>
            <fpage>50</fpage>
            <page-range>50-66</page-range>
            <pub-id pub-id-type="pmid">34399110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Zu</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Perfect match: mTOR inhibitors and tuberous sclerosis complex.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2022</year>
            <month>Mar</month>
            <day>04</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <pub-id pub-id-type="pmid">35246210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cascarino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leclerc-Mercier</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Histological Patterns of Skin Lesions in Tuberous Sclerosis Complex: A Panorama.</article-title>
            <source>Dermatopathology (Basel)</source>
            <year>2021</year>
            <month>Jul</month>
            <day>04</day>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>236</fpage>
            <page-range>236-252</page-range>
            <pub-id pub-id-type="pmid">34287284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altman</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Purser</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis: characteristics at CT and MR imaging.</article-title>
            <source>Radiology</source>
            <year>1988</year>
            <month>May</month>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>527</fpage>
            <page-range>527-32</page-range>
            <pub-id pub-id-type="pmid">3357966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassiri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Cortical tubers, cognition, and epilepsy in tuberous sclerosis.</article-title>
            <source>Pediatr Neurol</source>
            <year>2011</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>328</fpage>
            <page-range>328-32</page-range>
            <pub-id pub-id-type="pmid">21481739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lamm</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Houser</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex.</article-title>
            <source>J Child Neurol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-90</page-range>
            <pub-id pub-id-type="pmid">9075016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rebaine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Girerd</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Leroux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis complex for the pulmonologist.</article-title>
            <source>Eur Respir Rev</source>
            <year>2021</year>
            <month>Sep</month>
            <day>30</day>
            <volume>30</volume>
            <issue>161</issue>
            <pub-id pub-id-type="pmid">34348978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Henske</surname>
                <given-names>EP</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary manifestations in tuberous sclerosis complex.</article-title>
            <source>Am J Med Genet C Semin Med Genet</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>178</volume>
            <issue>3</issue>
            <fpage>326</fpage>
            <page-range>326-337</page-range>
            <pub-id pub-id-type="pmid">30055039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uysal</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>&#x0015e;ahin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis: a review of the past, present, and future.</article-title>
            <source>Turk J Med Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <day>03</day>
            <volume>50</volume>
            <issue>SI-2</issue>
            <fpage>1665</fpage>
            <page-range>1665-1676</page-range>
            <pub-id pub-id-type="pmid">32222129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capal</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2016</year>
            <volume>12</volume>
            <fpage>2165</fpage>
            <page-range>2165-72</page-range>
            <pub-id pub-id-type="pmid">27601910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oyerinde</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Buccine</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Treichel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Darling</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Fibrous cephalic plaques in tuberous sclerosis complex.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>717</fpage>
            <page-range>717-724</page-range>
            <pub-id pub-id-type="pmid">29258863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Janniger</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Micha&#x00142;owicz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chmielik</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance.</article-title>
            <source>Int J Dermatol</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>911</fpage>
            <page-range>911-7</page-range>
            <pub-id pub-id-type="pmid">9888331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoogeveen-Westerveld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ekong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Povey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lannoy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Elmslie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bebin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dies</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sparagana</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Eeghen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>van den Ouweland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nellist</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.</article-title>
            <source>Hum Mutat</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>167</fpage>
            <page-range>167-75</page-range>
            <pub-id pub-id-type="pmid">22903760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hasbani</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Crino</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Genetics of tuberous sclerosis complex: implications for clinical practice.</article-title>
            <source>Appl Clin Genet</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">28053551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Northrup</surname>
                <given-names>H</given-names>
              </name>
              <collab>International Tuberous Sclerosis Complex Consensus Group</collab>
            </person-group>
            <article-title>Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.</article-title>
            <source>Pediatr Neurol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>255</fpage>
            <page-range>255-65</page-range>
            <pub-id pub-id-type="pmid">24053983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <collab>participants of the TSC Consensus Meeting for SEGA and Epilepsy Management</collab>
            </person-group>
            <article-title>Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.</article-title>
            <source>Eur J Paediatr Neurol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>348</fpage>
            <page-range>348-52</page-range>
            <pub-id pub-id-type="pmid">23391693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahimi-Fakhari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1329</fpage>
            <page-range>1329-1336</page-range>
            <pub-id pub-id-type="pmid">32338549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tuberous sclerosis.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Aug</month>
            <day>23</day>
            <volume>372</volume>
            <issue>9639</issue>
            <fpage>657</fpage>
            <page-range>657-68</page-range>
            <pub-id pub-id-type="pmid">18722871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sooriakumaran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coughlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Attard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elmslie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corbishley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated.</article-title>
            <source>BJU Int</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-6</page-range>
            <pub-id pub-id-type="pmid">19493268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inaba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Egawa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex.</article-title>
            <source>Int J Urol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>780</fpage>
            <page-range>780-785</page-range>
            <pub-id pub-id-type="pmid">28905429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siroky</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Trout</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thamann</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Agricola</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Tudor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Capal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.</article-title>
            <source>J Pediatr</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>187</volume>
            <fpage>318</fpage>
            <page-range>318-322.e2</page-range>
            <pub-id pub-id-type="pmid">28600153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bissler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Radzikowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nonomura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brakemeier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peyrard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>111</fpage>
            <page-range>111-9</page-range>
            <pub-id pub-id-type="pmid">26156073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cordier</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lazor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Harari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reynaud-Gaubert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boehler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brauner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Popper</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bonetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kingswood</surname>
                <given-names>C</given-names>
              </name>
              <collab>Review Panel of the ERS LAM Task Force</collab>
            </person-group>
            <article-title>European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.</article-title>
            <source>Eur Respir J</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-26</page-range>
            <pub-id pub-id-type="pmid">20044458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in the management of lymphangioleiomyomatosis.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">29946430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Z&#x000f6;llner</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenow</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schubert-Bast</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiemer-Kruel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strzelczyk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC).</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2020</year>
            <month>Jan</month>
            <day>21</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">31964424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kurihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsuboshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seyama</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The effects of total pleural covering on pneumothorax recurrence and pulmonary function in lymphangioleiomyomatosis patients without history of pleurodesis or thoracic surgeries for pneumothorax.</article-title>
            <source>J Thorac Dis</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-124</page-range>
            <pub-id pub-id-type="pmid">33569191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Subependymal giant cell tumors in tuberous sclerosis complex.</article-title>
            <source>Neurology</source>
            <year>2004</year>
            <month>Oct</month>
            <day>26</day>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>1457</fpage>
            <page-range>1457-61</page-range>
            <pub-id pub-id-type="pmid">15505165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clarke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Foy</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Wetjen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Raffel</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Imaging characteristics and growth of subependymal giant cell astrocytomas.</article-title>
            <source>Neurosurg Focus</source>
            <year>2006</year>
            <month>Jan</month>
            <day>15</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>E5</fpage>
            <pub-id pub-id-type="pmid">16459995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kingswood</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Belousova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Benedik</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Curatolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dahlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Amato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>d'Aug&#x000e8;res</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Feucht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fladrowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Macaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabbout</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Youroukos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>AC</given-names>
              </name>
              <collab>TOSCA Consortium and TOSCA Investigators</collab>
            </person-group>
            <article-title>TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>630378</fpage>
            <pub-id pub-id-type="pmid">33833726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30666.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhoef</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tempelaars</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hesseling-Janssen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Mazurczak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jozwiak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fois</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartalini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zonnenberg</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>van Essen</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lindhout</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Halley</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>van den Ouweland</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>High rate of mosaicism in tuberous sclerosis complex.</article-title>
            <source>Am J Hum Genet</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>1632</fpage>
            <page-range>1632-7</page-range>
            <pub-id pub-id-type="pmid">10330349</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
